MBRX Reports $1.2M Revenue, $0.02 EPS, 40% CRc Rate in MIRACLE AML Trial, 45-Patient Unblinding Mid‑2026
Moleculin Biotech, Inc. · PHARMACEUTICAL PREPARATIONS · Now $2.64
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS